Adamas Pharmaceuticals Inc

NASDAQ:ADMS  
8.06
-0.01 (-0.12%)
Debt Financing / Related, Earnings Announcements

Supernus Pharmaceuticals To Acquire Adamas Pharmaceuticals

Published: 10/11/2021 15:51 GMT
Adamas Pharmaceuticals Inc (ADMS) - Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals Strengthening Its Cns Product Portfolio.
Supernus Pharmaceuticals Inc - Deal for Total Consideration Up to $9.10 per Share.
Supernus Pharmaceuticals Inc - Deal Expected to Be Significantly Accretive in 2022.
Supernus - Deal for Upfront Cash Payment of $8.10/share With Equity Value of About $400 Million, Plus $1.00 Cvr Based on Net Sales of Gocovri.
Supernus Pharmaceuticals Inc - Deal Cash Consideration Will Be Funded Through Existing Balance Sheet Cash.
Supernus Pharmaceuticals Inc - Expects Potential Synergies of $60 Million to $80 Million in Year One From Deal.
Revenue is expected to be $24.91 Million
Adjusted EPS is expected to be -$0.23

Next Quarter Revenue Guidance is expected to be $27.97 Million
Next Quarter EPS Guidance is expected to be -$0.18

More details on our Analysts Page.